Bioscience

ImmuneRegen BioSciences(R) Initiates Homspera(R) Studies Against Global Influenza Threat

October 14, 2009

By Flinn Foundation

[Source: Medical News Today] – ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.

For more information: ImmuneRegen BioSciences(R) Initiates Homspera(R) Studies Against Global Influenza Threat